Horn & Co. has been recognized again by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences.
April 15, 2018
Yuval Horn and Ohad Mamann of Horn & Co. represented Pontifax, who led a €16 million Series A round and restructuring in ABAC Therapeutics, Inc.
February 27, 2018
Who’s who legal – Data, Data, Data
February 1, 2018
An article (Hebrew) written by @Yuval Horn, @Roy Ribon and @Assaf Unger of Horn & Co., with respect to legal aspects of blockchain assets and cryptocurrency offerings, published on @themarker.
January 29, 2018
Yuval Horn, Paz Abercohen and Uri Dotan of Horn & Co. represented IOptima Ltd. and its shareholders, including Biolight Life Sciences Investments Ltd (TASE: BOLT) in a multi-stage acquisition transaction with an aggregate deal value of up to approximately $50 million, with Chengdu Kanghong Pharmaceutical Group, a Chinese life sciences company listed on the Shenzhen stock exchange.
November 28, 2017
Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. (Nasdaq: VBLT) in its $18.75 Million follow-on offering on NASDAQ.
November 26, 2017
Yuval Horn and Paz Abercohen of Horn & Co. acted as Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $9 Million private notes exchange agreement, and a $10 Million private placement of the company’s Secured Convertible Notes.
July 27, 2017
Horn & Co. ranked, again, by iam Magazine (Intellectual Asset Management) as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions
June 13, 2017
Yuval Horn, Keren Kanir, Ohad Mamann and Tammy Alon of Horn & Co., Law Offices represented Eloxx Pharmaceuticals Ltd. in its Series C financing round and simultaneous entering into an agreement for an acquisition transaction with Sevion Therapeutics, Inc.
June 4, 2017
Adv. Yuval Horn participated in the 5th Annual World Life Sciences Conference
June 1, 2017
